Cardiorenal Disease: Protect the Heart and Kidney Together

Student Handouts and Nephrology Primer · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Preserve indicated therapy by distinguishing manageable changes from genuine contraindications, and link each initiation to a specific monitoring plan.

Heart and kidney form a feedback loop. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Heart and kidney form a feedback loop. Cardiac dysfunction — Reduced forward flow or congestion; Kidney stress — Perfusion and venous pressure both matter; Neurohormonal activation — RAAS and sympathetic responses; Sodium and water retention — Can increase cardiac load. Match protective therapy to the heart-failure phenotype and monitor kidney function and potassium. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Define two phenotypes

Record EF and clinical heart-failure evidence alongside eGFR, UACR, potassium, BP, congestion, and perfusion. HFrEF, HFpEF, and albuminuric CKD overlap but do not carry identical drug indications. Diuretics treat fluid retention; they do not replace disease-modifying therapy.

HFrEF: build four complementary classes

When eligible and tolerated, use ARNI/ACE inhibitor/ARB, an evidence-based beta blocker, a steroidal MRA, and an SGLT2 inhibitor. Start and titrate around BP, pulse, volume, potassium, kidney function, and follow-up capacity; one universal sequence is unnecessary.

MRA selection has boundaries

For symptomatic HFrEF, spironolactone/eplerenone initiation requires eGFR >30 and K <5.0 mEq/L, with close follow-up. Stop if potassium cannot be maintained below 5.5. Finerenone has distinct diabetes/CKD and HF evidence; it is not automatically an interchangeable HFrEF substitute.

A creatinine rise needs a diagnosis

During effective decongestion, a modest rise with improving edema and maintained perfusion differs from shock, oliguria, or progressive injury. After ACE/ARB initiation, a rise >30% within 4 weeks triggers assessment for depletion, NSAIDs, AKI, or renovascular disease.

Revisit an old discontinuation

Reconsider protective therapy stopped after asymptomatic positive urine findings. Verify whether there was actual infection, symptomatic hypotension, severe hyperkalemia, or another contraindication. Restart eligible treatment with a dated BP, creatinine, potassium, and symptom review.

Measure the benefit relevant to this patient

SGLT2 therapy can be indicated despite HbA1c at target. Check drug-specific kidney eligibility and hold guidance during fasting, surgery, or critical illness. Do not attribute an individual eGFR decline entirely to a past drug stop or promise additive percentages across trials.

Supporting evidence

Continue learning